Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1067

A novel bioremediation technology for cleaning up per-and polyfluoroalkyl substances, or PFAS, chemical pollutants that threaten human health and ecosystem sustainability, has been developed by Texas A&M AgriLife researchers. The material has potential for commercial application for disposing of PFAS, also known as “forever chemicals.”

Published July 28 in Nature Communications, the was a collaboration of Susie Dai, Ph.D., associate professor in the Texas A&M Department of Plant Pathology and Microbiology, and Joshua Yuan, Ph.D., chair and professor in Washington University in St. Louis Department of Energy, Environmental and Chemical Engineering, formerly with the Texas A&M Department of Plant Pathology and Microbiology.

Removing PFAS contamination is a challenge

PFAS are used in many applications such as food wrappers and packaging, dental floss, fire-fighting foam, nonstick cookware, textiles and electronics. These days, PFAS are widely distributed in the environment from manufacturing or from products containing the chemicals, said Dai.

Read more | >

Dr. Arye Elfenbein, MD, PhD, is the Co-Founder of Wildtype (https://www.wildtypefoods.com/), a biotechnology company which produces cultured seafood (with a focus on cultivated Pacific salmon) from fish cells, sustainably and cost effectively, with the nutritional benefits, but without common contaminants such as mercury, microplastics, antibiotics, or pesticides, and without relying on commercial fishing or fish farming.

Born in Israel and raised in Australia, Dr. Elfenbein combines his deep passion for medicine and unique childhood connection to the ocean to fuel Wildtype’s health and environmental mission.

After studying at Dartmouth and Kyoto University, attaining a PhD and MD, Dr. Elfenbein began his residency at Yale where he first trained in Internal Medicine before completing training in Cardiology. After residency, he moved to San Francisco to work with Professor Dr. Deepak Srivastava at the revered Gladstone Institutes / UCSF, also known for being the scientific homes of Nobel laureates Dr. Shinya Yamanaka (iPs cells) and Dr. Jennifer Doudna (CRISPR).

During his time at the Gladstone Institutes, Dr. Elfenbein’s research focused on cardiac regeneration following heart attacks. This research inspired him to apply the principles of stem cell biology beyond medicine, and to address the growing problems in our food system.

Continue reading “Dr. Arye Elfenbein, MD, PhD — Co-Founder, Wildtype — Building A Better Food System” | >

Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round.

Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company’s stock price double.

Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget.

Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics.

Continue reading “Dr. Amber Salzman, PhD — CEO & Director, Epic Bio — Editing The Epigenome To Treat Complex Diseases” | >

Autism spectrum disorder (ASD) is a neurological and developmental condition that affects how humans communicate, learn new things and behave. Symptoms of ASD can include difficulties in interacting with others and adapting to changes in routine, repetitive behaviors, irritability and restricted or fixated interests for specific things.

While symptoms of autism can emerge at any age, the first signs generally start to show within the first two years of a child’s life. People with ASD can encounter numerous challenges, which can be addressed through support services, talk therapy and sometimes medication.

To this day, neuroscientists and have not identified the primary causes of ASD. Nonetheless, past findings suggest that it could be caused by the interaction of specific genes with environmental factors.

Read more | >

In our latest article, our Divisional Chief Nurse, Clare, discusses the social effects of friendships for people with learning disabilities and/or autism and the importance of those friendships. She also discusses how COVID-19 and the different restrictions have affected people with learning disabilities and/or autism and how best to support them.

Read more | >

MRI, electroencephalography (EEG) and magnetoencephalography have long served as the tools to study brain activity, but new research from Carnegie Mellon University introduces a novel, AI-based dynamic brain imaging technology which could map out rapidly changing electrical activity in the brain with high speed, high resolution, and low cost. The advancement comes on the heels of more than thirty years of research that Bin He has undertaken, focused on ways to improve non-invasive dynamic brain imaging technology.

Brain is distributed over the three-dimensional brain and rapidly changes over time. Many efforts have been made to image and dysfunction, and each method bears pros and cons. For example, MRI has commonly been used to study , but is not fast enough to capture brain dynamics. EEG is a favorable alternative to MRI technology however, its less-than-optimal spatial resolution has been a major hindrance in its wide utility for imaging.

Electrophysiological source imaging has also been pursued, in which scalp EEG recordings are translated back to the brain using and machine learning to reconstruct dynamic pictures of brain activity over time. While EEG source imaging is generally cheaper and faster, specific training and expertise is needed for users to select and tune parameters for every recording. In new published work, He and his group introduce a first of its kind AI-based dynamic brain imaging methodology, that has the potential of imaging dynamics of neural circuits with precision and speed.

Read more | >

The human brain is less accessible than other organs because it is covered by a thick, hard skull. As a result, researchers have been limited to low-resolution imaging or analysis of brain signals measured outside the skull. This has proved to be a major hindrance in brain research, including research on developmental stages, causes of diseases, and their treatments. Recently, studies have been performed using primary neurons from rats or human-derived induced pluripotent stem cells (iPSCs) to create artificial brain models that have been applied to investigate brain developmental processes and the causes of brain diseases. These studies are expected to play a key role to unlocking the mysteries of the brain.

In the past, artificial models were created and studied in 2D; however, in 2017, a research team from KIST developed a 3D artificial brain model that more closely resembled the real brain. Unfortunately, due to the absence of an analytical framework for studying signals in a 3D brain model, studies were limited to analyses of surface signals or had to reform the 3D structure to a flat shape. As such, tracking in a complex, interconnected artificial network remained a challenge.

The Korea Institute of Science and Technology (KIST) announced that the research teams of Doctors Il-Joo Cho and Nakwon Choi have developed a that can apply precise non-destructive stimuli to a 3D artificial neural circuit and measure neural signals in real-time from multiple locations inside the model at the cellular level.

Read more | >

Elementary school-age children who get less than nine hours of sleep per night have significant differences in certain brain regions responsible for memory, intelligence and well-being compared to those who get the recommended nine to 12 hours of sleep per night, according to a new study led by University of Maryland School of Medicine (UMSOM) researchers. Such differences correlated with greater mental health problems, like depression, anxiety, and impulsive behaviors, in those who lacked sleep. Inadequate sleep was also linked to cognitive difficulties with memory, problem solving and decision making. The findings were published today in the journal The Lancet Child & Adolescent Health.

The American Academy of Sleep Medicine recommends that aged six to 12 years of age sleep 9 to 12 hours per night on a regular basis to promote optimal health. Up until now, no studies have examined the long-lasting impact of insufficient sleep on the neurocognitive development of pre-teens.

To conduct the study, the researchers examined data that were collected from more than 8,300 children aged nine to 10 years who were enrolled in the Adolescent Brain Cognitive Development (ABCD) study. They examined MRI images, , and surveys completed by the participants and their parents at the time of enrollment and at a two-year follow-up visit at 11 to 12 years of age. Funded by the National Institutes of Health (NIH), the ABCD study is the largest long-term study of brain development and child health in the U.S.

Read more | >

A gene that University of Virginia (UVA) Health researchers have discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.

The new discovery may open the door to the first targeted treatments for two types of , a cancer of the soft tissue that primarily strikes young children.

The gene may also play an important role in other cancers that form in muscle, fat, nerves and other connective tissues in both children and adults, the research suggests.

Read more | >